The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
How does the micro-cap biotech now finance a 700-patient phase 3 study?
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.